Last reviewed · How we verify
Alphagan (BRIMONIDINE)
Alphagan (Brimonidine) is a small molecule alpha-Adrenergic Agonist that targets the Alpha-2C adrenergic receptor. It was originally developed by Senju Pharmaceutical Co., Ltd and is currently owned by Bausch And Lomb Inc. Alphagan is FDA approved for the treatment of ocular hypertension, open-angle glaucoma, and rosacea. The drug is available as a generic medication, with 14 generic manufacturers. Alphagan's commercial status is off-patent, allowing for generic competition.
At a glance
| Generic name | BRIMONIDINE |
|---|---|
| Sponsor | Senju Pharmaceutical Co., Ltd |
| Drug class | alpha-Adrenergic Agonist |
| Target | Alpha-2C adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
- Rosacea
Common side effects
- Allergic conjunctivitis
- Conjunctival hyperemia
- Eye pruritus
- Burning sensation
- Conjunctival folliculosis
- Hypertension
- Ocular allergic reaction
- Oral dryness
- Visual disturbance
- Abnormal taste
- Allergic reaction
- Asthenia
Serious adverse events
- Apnea
- Coma
- Respiratory depression
- Syncope
- Bradycardia
- Severe cardiovascular disease
- Hypotension
- Hypothermia
- Hypersensitivity
- Depression
Drug interactions
- phenelzine
- selegiline
- tranylcypromine
Key clinical trials
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Brimonidine 0.33% for Rosacea-Related Facial Erythema (PHASE4)
- High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia (NA)
- Upneeq vs. Lumify Ptosis (PHASE4)
- The PASTDUe Nutrition Ecosystem Project (PASTDUe) (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alphagan CI brief — competitive landscape report
- Alphagan updates RSS · CI watch RSS
- Senju Pharmaceutical Co., Ltd portfolio CI